Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Observed SARS-CoV-2 infections and deaths are low in tropical Africa raising questions about the extent of transmission. We measured SARS-CoV-2 IgG by ELISA in 9,922 blood donors across Kenya and adjusted for sampling bias and test performance. By 1st September 2020, 577 COVID-19 deaths were observed nationwide and seroprevalence was 9.1% (95%CI 7.6-10.8%). Seroprevalence in Nairobi was 22.7% (18.0-27.7%). Although most people remained susceptible, SARS-CoV-2 had spread widely in Kenya with apparently low associated mortality.
Article activity feed
-
SciScore for 10.1101/2021.02.09.21251404: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Blood donors gave individual written consent for the use of their samples for research. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Laboratory analyses: We tested samples for anti-SARS-CoV-2 IgG antibodies using a previously described a previously described ELISA for whole length spike antigen3 at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya. Assay sensitivity, estimated in sera from 174 PCR positive Kenyan adults and a panel of sera from the UK National Institute of Biological Standards and Control (NIBSC) was 92.7% (95% CI 87.9-96.1%); specificity, … SciScore for 10.1101/2021.02.09.21251404: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Blood donors gave individual written consent for the use of their samples for research. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Laboratory analyses: We tested samples for anti-SARS-CoV-2 IgG antibodies using a previously described a previously described ELISA for whole length spike antigen3 at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya. Assay sensitivity, estimated in sera from 174 PCR positive Kenyan adults and a panel of sera from the UK National Institute of Biological Standards and Control (NIBSC) was 92.7% (95% CI 87.9-96.1%); specificity, estimated in 910 serum samples from Kilifi drawn in 2018 was 99.0% (95% CI 98.1-99.5%)1. anti-SARS-CoV-2 IgGsuggested: Noneantigen3suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
-
